Dr. Dagi is a Managing Partner at the Salutramed Group, Inc, a consulting firm that provides analysis and support for critical decision-making for senior life science executives, for foundation and institutional executives and for boards of directors. He is also a venture capitalist investing in the life sciences, medical informatics and biomedical technologies. His portfolio has included Inhibitex (NASDAQ: INHX; acquired by Bristol Myers), Atherogenics (NASDAQ: AGIX), Racall, Teladoc, Encelle (acquired by Pioneer), Avigenics (NASDAQ: Synageva, NASDAQ:GEVA acquired by Alexion) NASDAQ: ALXN) and, Teladoc. He has served as a director on numerous public and private boards and presided over scientific advisory boards for Dupont, Lunbeck (USA) and the Royal Bank of Canada. His interests are focused on biomedical innovation, patient safety and effectiveness in healthcare delivery.

Prior to becoming a venture capitalist, Dr. Dagi was a practicing neurosurgeon credited with the development of cortical stimulating systems for epilepsy, intraventricular and spinal opiate delivery systems, and several surgical instruments. He was Section Chief at Brown University. Prior to that, he served at the NIH in the Laboratory for Cerebral Metabolism, held faculty appointments at Georgetown and the Massachusetts General Hospital.

Dr. Dagi is a director of the Anesthesia Patient Safety Foundation, the Council on Surgical and Perioperative Safety (CSPS), and the Beth Israel Deaconess Medical Center. He is the immediate past chair of the Committee on Perioperative Care of the American College of Surgeons and the CSPS. He is former chair of the Georgia Neurosurgical Society, and former director of the American Association of Neurological Surgeons, the Georgia Institute of Technology, the Wharton School of the University of Pennsylvania, the Goergen Entrepreneurial Institute, the Program in Biomedical Entrepreneurship of the Harvard-MIT Program in Health Sciences and Technology, the Georgia Biomedical Alliance, the Southeast Lifesciences Investor Association, and the Georgia Entrepreneur Foundation. He was a delegate to the US-Israel Science and Technology Foundation and helped found the Israel Life Sciences Association. He was appointed to advise on biotechnology initiatives in Northern Ireland, and to CURAM, the medical device initiative as part of the National University of Ireland in Galway. As special assistant to the Assistant Secretary of Defense for Health Affairs, he developed and implemented logistics for medical support during the first Gulf War. He also served as special assistant to the Secretary of the Administrative Conference, and medical advisor to the Office of Technology Assessment of the Congress of the United States. He served at the FDA on the panel for neurological drugs and devices. He has advised sovereign governments, states and universities on life science and biomedical investment and innovation initiatives.

Dr. Dagi holds academic appointments at Harvard Medical School and Queen’s University Belfast, where he chairs the advisory panel for the School of Medicine. He serves on the faculty of the NVCA’s Venture Capital Institute and has lectured on innovation in health care at Harvard Business School. He has authored or edited eight books and over 150 articles and chapters. He received an AB from Columbia College, MD and MPH from Johns Hopkins, MBA from Wharton, the DMedSc from Queen’s University Belfast, and a DHC from the Kaunas Technical Institute in Lithuania He completed his neurosurgical training at the Massachusetts General Hospital and Harvard, where he was a Neuroresearch Foundation Fellow and  the Joseph P. Kennedy, Jr, Fellow, and in London.

Dr. Dagi is board certified in neurological surgery and qualified in international health and flight medicine. For his work in international disaster assistance, he was awarded the US Humanitarian Service Medal and Fellowship in the College of Critical Care Medicine. He was recently granted Fellowship ad hominem by the Royal College of Surgeons of Edinburgh.